CAMBRIDGE, Mass.—Genzyme Corp. announced Aug. 10 that it has launched a 1 mcg formulation of Hectorol (doxercalciferol capsules).
The 1 mcg capsules provide a new dosing option for patients and healthcare providers, in addition to the existing 0.5 mcg and 2.5 mcg capsules, according to Genzyme.
“The launch of the new 1 mcg strength of Hectorol Capsules is an example of Genzyme’s ongoing effort to enhance the care of patients with chronic kidney disease,” stated Dan Regan, senior vice president and general manager of Genzyme’s renal business. “This formulation provides added dosing flexibility for physicians and convenience for patients.”
Hectorol Capsules are indicated for the treatment of secondary hyperparathyroidism in patients with stage 3 or stage 4 chronic kidney disease (CKD); the recommended starting dose for these patients is 1 mcg per day, according to Genzyme. Hectorol Capsules are also indicated for CKD patients who are on dialysis.
